BMB 101
Alternative Names: BMB-101Latest Information Update: 28 Jul 2025
At a glance
- Originator Bright Minds Biosciences; Firefly Neuroscience
- Developer Bright Minds Biosciences
- Class Antiepileptic drugs; Behavioural disorder therapies; Drug withdrawal therapies
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Absence epilepsy; Pitt-Hopkins syndrome
- Preclinical Binge-eating disorder; Lennox-Gastaut syndrome; Opioid-related disorders
- No development reported Dravet syndrome
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Dravet-syndrome(In volunteers) in Australia (PO)
- 13 May 2025 Pharmacodynamics data from the preclinical trial in Epilepsy released by Bright Minds Biosciences
- 21 Oct 2024 Firefly Neuroscience and Bright Minds Biosciences collaborates for the development of BMB 101 for Pitt-Hopkins syndrome